Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amanda Johnson

Vascular & Interventional Radiology Calhoun City, MS Doctor of Osteopathy

NPI 1942511456 CMS profile 4225462

140 Burke Calhoun City Rd, Calhoun City, MS 38916

Open in the dashboard

General payments

$2,205

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Johnson of Calhoun City, MS is reported in the CMS Open Payments database as having received $2,205 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $432 12
2024 General $144 7
2023 General $245 9
2022 General $566 16
2021 General $343 14
2020 General $155 8
2019 General $321 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Johnson
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Amanda Johnson were reported at $432. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Amanda Johnson Vascular & Interventional Radiology median Middle half National median
2019 $321 $422 $125–$1,555 $163
2020 $155 $200 $68–$652 $114
2021 $343 $280 $99–$866 $132
2022 $566 $433 $137–$1,497 $149
2023 $245 $506 $152–$2,019 $160
2024 $144 $556 $175–$1,930 $164
2025 $432 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,220 37 payments
  2. Medtronic USA, Inc. $448 23 payments
  3. Boston Scientific Corporation $167 7 payments
  4. Penumbra, Inc. $165 6 payments
  5. Argon Medical Devices, Inc. $48 3 payments
  6. Bard Peripheral Vascular, Inc. $43 1 payment
  7. Terumo Medical Corporation $38 2 payments
  8. Siemens Medical Solutions USA, Inc. $28 1 payment
  9. Medtronic Vascular, Inc. $28 2 payments
  10. Biogen, Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,205 83 payments
Products named General payments · program years 2019–2025
  1. KYPHON EXPRESS II KYPHOPAK TRAY $583 10 payments
  2. OSTEOCOOL RF ABLATION SYSTEM $302 12 payments
  3. KYPHON Balloon Kyphoplasty Neuro Pain (includes Interventional) $302 15 payments
  4. OSTEOCOOL RF ABLATION Neuro Pain (includes Interventional) $146 8 payments
  5. OSTEOCOOL RF ABLATION Neuro Pain (includes Interventional) $114 4 payments
  6. Indigo System $102 3 payments
  7. KYPHON Balloon Kyphoplasty Neuro Pain (includes Interventional) $98 5 payments
  8. Cryoablation needles $52 1 payment
  9. SOLITAIRE X $47 2 payments
  10. Solitaire $44 2 payments
  11. Other $357 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 214 billing codes

Paid by Medicare

$221,635

Of which drugs: $540

Medicare patients

3,109

Average age 74

Services billed

10,411

1,669 women, 1,440 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 49%
Diabetes 45%
Chronic kidney disease 38%
COPD 34%
Depression 34%
Heart failure 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 46 4,645 $481

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record